Published in Kidney Int on April 01, 1999
What is nephrocalcinosis? Kidney Int (2015) 1.08
Mechanisms of human kidney stone formation. Urolithiasis (2014) 0.92
The effect of ions at the surface of calcium oxalate monohydrate crystals on cell-crystal interactions. Urol Res (2003) 0.91
Unconventional chemiosmotic coupling of NHA2, a mammalian Na+/H+ antiporter, to a plasma membrane H+ gradient. J Biol Chem (2012) 0.84
The tubular epithelium in the initiation and course of intratubular nephrocalcinosis. Urol Res (2010) 0.83
Calcium oxalate calculi-induced clusterin expression in kidney. Urolithiasis (2015) 0.79
The effect of intracrystalline and surface-bound osteopontin on the degradation and dissolution of calcium oxalate dihydrate crystals in MDCKII cells. Urol Res (2011) 0.78
Antioxidant Pre-Treatment Reduces the Toxic Effects of Oxalate on Renal Epithelial Cells in a Cell Culture Model of Urolithiasis. Int J Environ Res Public Health (2017) 0.75
Histological aspects of the "fixed-particle" model of stone formation: animal studies. Urolithiasis (2016) 0.75
Pregnane X receptor and yin yang 1 contribute to the differential tissue expression and induction of CYP3A5 and CYP3A4. PLoS One (2012) 0.75
The effect of traditional risk factors for stone disease on calcium oxalate crystal adherence in the rat bladder. Urol Res (2007) 0.75
Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med (2004) 16.58
Transcription factor Sp1 is essential for early embryonic development but dispensable for cell growth and differentiation. Cell (1997) 3.17
Microscopic haematuria. BMJ (1994) 3.00
Prostate cancer: to screen or not to screen? BMJ (1993) 2.41
Mammalian Golgi-associated Bicaudal-D2 functions in the dynein-dynactin pathway by interacting with these complexes. EMBO J (2001) 2.34
Health-related quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancer. J Clin Oncol (2001) 2.33
Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram. J Urol (2007) 2.26
The POU factor Oct-6 and Schwann cell differentiation. Science (1996) 2.17
Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Am J Pathol (1994) 1.94
The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population. J Urol (1997) 1.67
Adrenal glands of mouse and rat do not synthesize androgens. Life Sci (1992) 1.64
Pathologic features of prostate cancer found at population-based screening with a four-year interval. J Natl Cancer Inst (2001) 1.63
Cutaneous metastasis following laparoscopic pelvic lymphadenectomy for prostatic carcinoma. J Urol (1995) 1.59
Future prospects in prostate cancer. Prostate (1999) 1.53
A mouse model for the basal transcription/DNA repair syndrome trichothiodystrophy. Mol Cell (1998) 1.52
Anxiety and depression after prostate cancer diagnosis and treatment: 5-year follow-up. Br J Cancer (2006) 1.51
Sperm DNA integrity in cancer patients before and after cytotoxic treatment. Hum Reprod (2010) 1.45
Screening for prostate cancer--more questions than answers. Acta Oncol (1998) 1.40
Errors in transrectal ultrasonic planimetry of the prostate: computer simulation of volumetric errors applied to a screening population. Ultrasound Med Biol (1995) 1.39
Treatment of benign prostatic hyperplasia by transurethral ultrasound-guided laser-induced prostatectomy (TULIP): effects on urodynamic parameters and symptoms. Urology (1994) 1.39
[Diagnosis based on prostate needle biopsy: inadequate correlation between pathologic results and clinical course for individual prognosis]. Ned Tijdschr Geneeskd (2005) 1.37
Short-term effects of population-based screening for prostate cancer on health-related quality of life. J Natl Cancer Inst (1998) 1.36
European Randomized Study of Screening for Prostate Cancer: achievements and presentation. BJU Int (2003) 1.32
Membrane targeting of cGMP-dependent protein kinase is required for cystic fibrosis transmembrane conductance regulator Cl- channel activation. Proc Natl Acad Sci U S A (1998) 1.31
Features and preliminary results of the Dutch centre of the ERSPC (Rotterdam, the Netherlands). BJU Int (2003) 1.30
Detection of prostate cancer. BMJ (1995) 1.30
Development of seven new human prostate tumor xenograft models and their histopathological characterization. Am J Pathol (1996) 1.29
Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM). Urology (2004) 1.25
Modalities available for screening for prostate cancer. Eur J Cancer (1993) 1.23
Calcium oxalate nephrolithiasis: effect of renal crystal deposition on the cellular composition of the renal interstitium. Am J Kidney Dis (1999) 1.20
Identification of genetic markers for prostatic cancer progression. Lab Invest (2000) 1.19
A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer screening in Rotterdam, Netherlands. Br J Cancer (2010) 1.16
Chemosensitivity of prostate cancer cell lines and expression of multidrug resistance-related proteins. Eur J Cancer (1999) 1.16
Natural history of benign prostatic hyperplasia: appropriate case definition and estimation of its prevalence in the community. Urology (1995) 1.15
Generalized glycogen storage and cardiomegaly in a knockout mouse model of Pompe disease. Hum Mol Genet (1998) 1.14
5-Aminolaevulinic acid-induced protoporphyrin IX accumulation in tissues: pharmacokinetics after oral or intravenous administration. J Photochem Photobiol B (1998) 1.14
Molecular cytogenetic analysis of prostatic adenocarcinomas from screening studies : early cancers may contain aggressive genetic features. Am J Pathol (2001) 1.11
Additional use of [-2] precursor prostate-specific antigen and "benign" PSA at diagnosis in screen-detected prostate cancer. Urology (2005) 1.11
Why do men refuse or attend population-based screening for prostate cancer? J Public Health Med (2000) 1.11
Progression in and survival of patients with locally advanced prostate cancer (T3) treated with radical prostatectomy as monotherapy. J Urol (1998) 1.10
Human acid alpha-glucosidase from rabbit milk has therapeutic effect in mice with glycogen storage disease type II. Hum Mol Genet (1999) 1.10
Bladder calculi in augmentation cystoplasty in children. Urology (2000) 1.08
Positive margins after radical prostatectomy: correlation with local recurrence and distant progression. Br J Urol (1993) 1.08
Monoclonal antibodies against human beta-glucocerebrosidase. Eur J Biochem (1983) 1.08
Orthotopic implantation of human prostate cancer cell lines: a clinically relevant animal model for metastatic prostate cancer. Prostate (1997) 1.07
Prospective evaluation plan for randomised trials of prostate cancer screening. The International Prostate Cancer Screening Trial Evaluation Group. J Med Screen (1996) 1.06
Hormonal manipulation of prostatic cancer. BMJ (1991) 1.06
Use of nude mouse xenograft models in prostate cancer research. Prostate (2000) 1.05
Prognostic value of cell cycle proteins p27(kip1) and MIB-1, and the cell adhesion protein CD44s in surgically treated patients with prostate cancer. J Urol (2000) 1.05
Characterization of the prostate-specific antigen gene: a novel human kallikrein-like gene. Biochem Biophys Res Commun (1989) 1.05
Overdiagnosis and overtreatment of early detected prostate cancer. World J Urol (2007) 1.05
Radical nephrectomy with and without lymph node dissection: preliminary results of the EORTC randomized phase III protocol 30881. EORTC Genitourinary Group. Eur Urol (1999) 1.04
Quebec randomized controlled trial on prostate cancer screening shows no evidence for mortality reduction. Prostate (1999) 1.04
Increased calcium oxalate monohydrate crystal binding to injured renal tubular epithelial cells in culture. Am J Physiol (1998) 1.04
Effects of extracorporeal shock wave lithotripsy (ESWL) on renal tissue. A review. Urol Res (1989) 1.04
Reasons for the weak correlation between prostate volume and urethral resistance parameters in patients with prostatism. J Urol (1995) 1.03
Regulation of the C3 nephritic factor stabilized C3/C5 convertase of complement by purified human erythrocyte C3b receptor. Clin Exp Immunol (1982) 1.03
Role of macrophages in nephrolithiasis in rats: an analysis of the renal interstitium. Am J Kidney Dis (2000) 1.02
Association of calcium oxalate monohydrate crystals with MDCK cells. Kidney Int (1995) 1.01
Screening for prostate cancer. Eur J Cancer (2005) 1.01
A distal Schwann cell-specific enhancer mediates axonal regulation of the Oct-6 transcription factor during peripheral nerve development and regeneration. EMBO J (2000) 1.01
Tissue specific and androgen-regulated expression of human prostate-specific transglutaminase. Biochem J (1996) 1.01
Management of benign prostatic hyperplasia with particular emphasis on aromatase inhibitors. J Steroid Biochem Mol Biol (1993) 1.00
Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group. World J Urol (2011) 1.00
Excessive crystal agglomeration with low citrate excretion in recurrent stone-formers. Lancet (1986) 1.00
Repeat screening for prostate cancer after 1-year followup in 984 biopsied men: clinical and pathological features of detected cancer. J Urol (1998) 0.99
Abnormal urine flow in boys with distal hypospadias before and after correction. J Urol (2006) 0.98
Individual and interindividual differences in binocular retinal rivalry in man. Psychophysiology (1966) 0.98
Effects of low testosterone levels and of adrenal androgens on growth of prostate tumor models in nude mice. J Steroid Biochem Mol Biol (1990) 0.98
The role in CaCO3 crystallization of an acid Ca2+-binding polysaccharide associated with coccoliths of Emiliania huxleyi. Eur J Biochem (1982) 0.98
The value of (-7, -5)pro-prostate-specific antigen and human kallikrein-2 as serum markers for grading prostate cancer. BJU Int (2004) 0.98
Value of tissue markers p27(kip1), MIB-1, and CD44s for the pre-operative prediction of tumour features in screen-detected prostate cancer. J Pathol (2002) 0.97
Long-term effects of buserelin on plasma testosterone and luteinising hormone concentrations. Lancet (1985) 0.97
Comparison of sequence and function of the Oct-6 genes in zebrafish, chicken and mouse. Mech Dev (1998) 0.97
The interobserver variability of digital rectal examination in a large randomized trial for the screening of prostate cancer. Prostate (2008) 0.97
Castration-induced changes in morphology, androgen levels, and proliferative activity of human prostate cancer tissue grown in athymic nude mice. Prostate (1993) 0.97
Time-resolved ESR and chemically induced dynamic electron polarisation of the primary reaction in a reaction center particle of Rhodopseudomonas sphaeroides wild type at low temperature. FEBS Lett (1977) 0.97
Parameters of prostate volume and shape in a community based population of men 55 to 74 years old. J Urol (1994) 0.96
Identification and androgen-regulated expression of two major human glandular kallikrein-1 (hGK-1) mRNA species. Mol Cell Endocrinol (1991) 0.96
Serendipity in detecting disease in low prostate-specific antigen ranges. BJU Int (2002) 0.96
Branching and differentiation defects in pulmonary epithelium with elevated Gata6 expression. Mech Dev (2001) 0.96
The human prostatic cancer cell line LNCaP and its derived sublines: an in vitro model for the study of androgen sensitivity. J Steroid Biochem Mol Biol (1991) 0.96
Do neuroendocrine cells in human prostate cancer express androgen receptor? Histochemistry (1993) 0.96
Vanished testis: be aware of an abdominal testis. J Urol (2000) 0.96